News
In the laboratory, induced pluripotent stem (iPS) cells can seem like magic: derived from...
September 29, 2021
Financing will accelerate momentum toward unlocking the linearity between discovery and...
September 28, 2021
NIH/NIAID SBIR Fast Track grant accelerates the company’s commercial activities towards a non-viral...
June 15, 2021
The 2021 Cellicon Valley Symposium is presented by Penn’s Abramson Cancer Center and Children’s...
April 30, 2021
What if a cancer patient could receive life-saving cellular therapy within days of diagnosis rather...
April 14, 2021
2021 Cell & Gene Meeting on the Med organized by the Alliance for Regenerative Medicine, was held...
April 06, 2021
Greg Crescenzi Joins Kytopen as Chief Commercial Officer to Drive Discovery, Development and...
March 29, 2021
BioCentriq™, the New Jersey Innovation Institute’s cell and gene therapy development and...
March 23, 2021
Kytopen co-founder Professor Cullen Buie studied mechanical engineering, first at Ohio State, then...
February 02, 2021
MIT spin-out company Kytopen has engaged Cambridge Consultants to co-develop the first Flowfect™...
January 20, 2021